Quintiles Recieves Phase II/III Clinical Research Industry Accolade
News May 22, 2013
Quintiles is the industry leader that best differentiates itself on service quality in Phase II/III clinical research, according to 157 pharmaceutical and biotechnology professionals who responded to Industry Standard Research’s (ISR) 2013 CRO Quality Benchmarking Report – Phase II/III. Respondents also rated Quintiles as the leader among large CROs for customer loyalty, defined by overall satisfaction, willingness to recommend and likelihood to use Quintiles again.
“We are deeply committed to helping our customers increase their probability of success at every stage of the product lifecycle,” said Paula Brown Stafford, President, Clinical Development at Quintiles. “We are delighted to see that our leadership and commitment to both quality and customer satisfaction are recognized by the industry.”
According to the report:
• Quintiles is the best Phase II/III clinical research service provider at differentiation based on service quality;
• Quintiles leads large CROs in customer loyalty and is the most cited industry leader;
• Quintiles most consistently meets customer expectations, and is the leader among large CROs in exceeding expectations for global reach, breadth of services, local regulatory knowledge, commercial market knowledge and the ability to consistently meet “First Patient In” timelines.
Survey respondents also recognized Quintiles as a leader among large CROs for meeting customer expectations for real-time access to data. Quintiles is committed to transforming drug development through its data and proprietary knowledge engine, Quintiles Infosario®, an innovative solution that seamlessly integrates data, Quintiles’ systems, processes and therapeutic expertise to help customers make faster, more informed decisions.
Sartorius Stedim Biotech and Siemens Sign Automation AgreementNews
Siemens becomes a preferred supplier for automation solutions. Product portfolio of Sartorius Stedim Biotech to feature a globally standardized automation platform in the future.READ MORE
Microbiotica Enters into Microbiome Collaboration with GenentechNews
Strategic collaboration for microbiome biomarker signatures and therapeutic discovery based on Genentech’s inflammatory bowel disease pipeline.READ MORE
Chemoradiotherapy Before Surgery Could Extend Lives of Pancreatic Cancer PatientsNews
Pancreatic cancer patients treated with chemotherapy and radiotherapy before surgery may live longer than those who have immediate surgery, according to unpublished clinical trial results.READ MORE